SCHEMBL26425757

SCHEMBL26425757

CN1C(=O)/C(=C/c2c[nH]c3ccccc23)NC1=S

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.62
IDH1 O75874 8/20 0.53
ALDH1A1 P00352 4/20 0.51
MAPT P10636 4/20 0.51
HPGD P15428 2/20 0.51
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NTRK1 P04629 2/20 0.46
DAPK3 O43293 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837909 0.88 KDM4E (0.49) AHRALDH1A1MAPTHPGDKMT2A
SCHEMBL860566 0.88 KDM4E (0.49) AHRALDH1A1MAPTHPGDKMT2A
SCHEMBL837908 0.88 KDM4E (0.49) AHRALDH1A1MAPTHPGDKMT2A
SCHEMBL23578886 0.84 IDH1 (0.56) AHRIDH1ALDH1A1MAPTHPGD
SCHEMBL23578887 0.84 IDH1 (0.56) AHRIDH1ALDH1A1MAPTHPGD
SCHEMBL30343490 0.84 IDH1 (0.56) AHRIDH1ALDH1A1MAPTHPGD
SCHEMBL1714562 0.80 IDH1 (0.61) AHRIDH1ALDH1A1MAPTHPGD
SCHEMBL1714561 0.80 IDH1 (0.61) AHRIDH1ALDH1A1MAPTHPGD
SCHEMBL19820158 0.78 MAPT (0.57) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL24251256 0.77 MAPT (0.60) ALDH1A1MAPTHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP AHR 4344/4885IDH1 2533/4885ALDH1A1 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.